1	Integrated metagenomic and bile acid metabolomic analysis of human fecal microbiota
2	transplantation for recurrent Clostridioides difficile and/or inflammatory bowel diseases.
3	
4	Ruben Jesus Faustino Ramos ¹ , Chencan Zhu ² , Dimitri F Joseph ^{3#a} , Shubh D Thaker ³ , Joseph F
5	LaComb ³ , Katherine Markarian ⁴ , Eric R. Littmann ^{5†} , Hannah J Lee ^{3#b} , Jessica C Petrov ^{3#c} , Farah
6	Monzur ³ , Bradley M Morganstern ^{3#d} , Juan Carlos Bucobo ³ , Jonathan M Buscaglia ³ , Anupama
7	Chawla ³ , Lesley Small-Harary ⁴ , Grace Gathungu ⁴ , Jeffrey A Morganstern ⁴ , Jie Yang ^{2,6,7} , Jinyu
8	Li ^{6,8} , Charles E Robertson ⁹ , Eric G. Pamer ⁵ , Daniel N Frank ⁹ , Justin R Cross ¹ , Ellen Li ^{3*}
9	
10	¹ Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering
11	Cancer Center, New York City, New York, United States of America
12	² Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, New
13	York, United States of America
14	³ of Medicine, Stony Brook University, Stony Brook, New York, United States of America
15	⁴ Department of Pediatrics, Stony Brook University, Stony Brook, New York, United States of
16	America
17	⁵ Department of Medicine, University of Chicago, Chicago, Illinois, United States of America
18	⁶ Department of Family, Population and Preventive Medicine, Stony Brook University, New York,
19	United States of America
20	⁷ Biostatistics and Data Science Stony Brook Cancer Center Shared Resource, Stony Brook
21	University, New York, United States of America
22	⁸ Department of Pathology, Stony Brook University, Stony Brook, New York, United States of
23	America
24	⁹ Department of Medicine, University of Colorado - Denver, Aurora, Colorado, United States of
25	America
26	#aD.O-Ph.D program, Michigan State University, East Lansing, United States of America

- 27 ^{#b}Internal Medicine-Pediatrics Residency Program, University of Texas Southwestern, Dallas,
- 28 United States of America
- 29 ^{#c}Internal Medicine Residency Program, Yale University, New Haven, Connecticut, United States
- 30 of America
- 31 ^{#d}New York University-Langone Hospital-Long Island, Mineola, New York, United States of
- 32 America
- 33 *Corresponding author, e-mail: ellen.li@stonybrookmedicine.edu
- 34 [†]deceased
- 35
- 36

37 Abstract

38 Background

Fecal microbiota transplantation (FMT) is an effective treatment of recurrent *Clostridioides difficile* infections (rCDI). In comparison, FMT has more limited efficacy in treating either ulcerative colitis (UC) or Crohn's disease (CD), two major forms of inflammatory bowel diseases (IBD). We hypothesize that FMT recipients with rCDI and/or IBD have baseline fecal bile acid (BA) compositions that differ significantly from that of their healthy donors and may be normalized by FMT.

45 **Aim**

46 To study the effect of single colonoscopic FMT on the microbial composition and function of 47 recipients with rCDI and/or IBD.

48 Methods

Multi-omic analysis was performed on stools from 55 pairs of subjects and donors enrolled in two prospective single arm FMT clinical trials [ClinicalTrials.gov ID:NCT03268213, 479696, (IND) 15642, ClinicalTrials.gov ID: NCT03267238, IND 16795]. Fitted linear mixed models were used to examine the effects of four recipient groups (rCDI - IBD, rCDI + IBD, UC - rCDI, CD - rCDI), FMT status (Donor, pre-FMT, 1-week post-FMT, 3-months post-FMT) and first order Group*FMT interactions.

55 Results

56 FMT was effective in preventing rCDI for up to one year in 92% of the rCDI - IBD group and 75% 57 of the rCDI + IBD recipients. The donor-recipient Sørensen similarity index was < 0.6 in all donor-58 CDI recipient pairs but > 0.6 in some donor-IBD only recipient pairs at baseline. Increasing post-59 FMT similarity indices > 0.6 in IBD recipients, was not clearly associated with reduced fecal 50 calprotectin levels. Fecal secondary BA levels were lower in rCDI ± IBD and CD – rCDI recipients 51 compared to donors. FMT restored secondary BA levels in these recipients. Metagenomic *baiE*

gene and some of the 8 bile salt hydrolase (BSH) phylotype abundances were significantly
 correlated with fecal BA levels.

64 **Conclusion**

Restoration of multiple secondary BA levels, including those recently implicated in
 immunomodulation, are associated with restoration of fecal *baiE* gene counts, suggesting that the
 7-α-dehydroxylation step is rate-limiting.

68

69 Introduction

FMT of healthy donor stool is a highly effective treatment of rCDI [1-4]. Patients with IBD, particularly UC, indeterminate colitis (IC) and Crohn's colitis (CC), are at increased risk of developing CDI [5-9], and FMT is an effective treatment of rCDI in these patients [10-15]. However, studies thus far on the effectiveness of FMT in the treatment of IBD, absent concomitant CDI, have utilized different protocols and have yielded mixed results [16-27].

75 Restoration of bacterial metabolism of primary BA to secondary has been implicated in 76 the mechanism by which FMT promotes resistance to CDI [28]. Primary conjugated BA 77 synthesized in the liver are released into the gut lumen upon feeding and serve to emulsify dietary 78 fats. Within the gut lumen, conjugated BA undergo deconjugation by bacterial bile salt hydrolases 79 (BSH) in the small intestine [29]. While most of BA from the small intestine by enterohepatic 80 circulation and transported back to the liver, a fraction reaches the colon and undergoes further 81 conversion by bacterial enzymes, such as 7-alpha dehydroxylase, to form secondary BA. 7-alpha 82 dehydroxylating bacteria, such as *Clostridium scindens*, have been shown to be reduced in rCDI 83 patients and replenishment of these bacteria was demonstrated to inhibit CDI in an animal model 84 [28]. More recently, epimers of deoxycholic and lithocholic acids (e.g. iso-deoxycholic, 3-oxo-85 lithocholic, isoallo-lithocholic acids) have been demonstrated to have in vitro immunomodulatory

activity [30-32]. Modified BA pool composition has been observed in IBD patients [33-35], with
altered levels of some BA epimers that exhibit potential immunomodulatory effects.

88 At Stony Brook University Medical Center (SBUMC), we have been conducting two 89 prospective single arm clinical trials: 1.) ClinicalTrials.gov ID:NCT03268213, 479696, UC only 90 Investigational New Drug (IND) 15642 and 2.) ClinicalTrials.gov ID: NCT03267238, CD only IND 91 16795, to examine the longitudinal microbiological and clinical effects of single donor FMT on the 92 fecal microbiome in four groups of recipients: rCDI without IBD (rCDI – IBD); rCDI with IBD (rCDI 93 + IBD); UC without rCDI (UC - rCDI); CD without rCDI (CD - rCDI, see Fig 1). Each FMT recipient 94 selected their own donor, who was subsequently screened for pathogens and antibiotic resistant 95 bacteria. This FMT study is unique in that it includes prospective collection of a relatively large 96 set of healthy donor stools. The results of 16S rRNA sequence analysis of single donor 97 colonoscopic FMT performed on a subset of 19 recipients was previously reported [36], which 98 included: 1) 11 rCDI – IBD; 2) 3 rCDI + UC; and 3) 5 UC - rCDI. The previous results indicated 99 marked changes in β diversity (i.e. overall microbiome composition differences between groups) 100 in the rCDI + UC and rCDI – IBD groups (compared to donors). The rCDI - IBD and rCDI + UC 101 recipients had a marked decreased abundances of anaerobic taxa in the Ruminococcaceae, (e.g. 102 Faecalibacterium) and Lachnospiraceae groups, and marked increased abundances of 103 microaerophilic taxa in the Bacilli group, and Proteobacteria and Fusobacteria phyla, which were 104 restored post FMT. In contrast the pre-FMT differences in β-diversity were much more subtle in 105 the UC - rCDI group compared to their healthy donors. These differences were characterized by 106 increased abundances of microaerophilic taxa in the Bacilli, Proteobacteria and Fusobacteria in the UC - rCDI group. 107

108

109 Fig 1. Schematic diagram of recipient group and donor fecal sample collection.

110

We now report the results of multi-omic analysis (16S rRNA gene sequencing, metabolomics analysis and shotgun DNA metagenomics sequencing) of the effect of colonoscopic single donor FMT in an expanded set of recipients separated into four categories: 1.) rCDI - IBD; 2.) rCDI + IBD; 3.) UC - rCDI; 4.) CD - rCDI (see Fig 1).

115

116 Materials and methods

117 Study protocols

118 The patient and donors were recruited through two open label study protocols (See S1-S2 text 119 for IRB approved protocols). Clinical Trials.gov ID NCT03268213, 479696, UC no rCDI \ge 2x IND 120 15642, was approved by the Stony Brook Institutional Review Board (479696) on 11/14/2013. 121 Clinical Trials.gov ID NCT03267238, IND 16795, was approved by Stony Brook Institutional 122 Review Board (973349) on 06/16/2017 (see S1 Table Transparent Reporting of Evaluations with 123 Nonrandomized Designs (TREND) checklist). The initial recipient/donor pair was recruited on 124 12/05/2013. The final recipient/donor included in this report were recruited 06/19/2019. There was 125 a delay in the registration of NCT03268213 on Clinical Trials.gov relative to the initial recruitment 126 of the first recipient/donor pairs as described previously [37], but no delay in the registration of 127 NCT03267238 relative to the initial recruitment of patient/donor pairs. For the patients with rCDI 128 (with or without IBD), the inclusion criteria were ≥ 2 recurrences despite treatment with antibiotics. 129 documented by \geq 3 positive stool tests for CDI (see Fig 1). For the patients with UC without a 130 history of rCDI \ge 2x, the inclusion criterion was medication refractory UC, requiring step up therapy 131 beyond mesalamine alone. Only one of the patients in this group had a distant prior history of CDI 132 with the last episode 2 years prior to the procedure. For the patients with CD without a history of 133 rCDI \ge 2x, the inclusion criterion was medication refractory CD, requiring step up therapy beyond 134 mesalamine alone. None of the CD patients had a history of previous CDI. Exclusion criteria for 135 all of the recipients included: a) scheduled for abdominal surgery within 12 weeks of the study, b)

136 pregnancy, c) Grade 4 anemia (Hemoglobin < 6 g/dL), d) Grade 1 neutropenia (Absolute 137 Neutrophil Count <1500), e) known diagnosis of graft vs. host disease, f) major abdominal surgery 138 within the past 3 months, a) administration of any investigational drug within the past 2 months. 139 h) use of a TNF- α antagonist within 2 weeks of the proposed date of transplantation, i) bacteremia 140 within past 4 weeks. (28 days), and j.) adults ≥18 years unable to or unwilling to give informed 141 consent. The CONSORT flow diagram is outlined in Fig 2. Recruitment and collection of data 142 and processing of patient samples were conducted as previously described in Mintz et al. 143 [36]. The IBD subphenotypes were classified using the Montreal classification in terms of disease 144 location (L1, ileal CD; L2, Crohn's colitis; L3, ileocolitis; L4, upper gastrointestinal) for CD and 145 extent of disease (E1, proctitis; E2, left-sided UC; E3, extensive UC proximal to splenic flexure) 146 for UC [37]. Mucosal disease activity in the colon and the terminal ileum at the time of the 147 colonoscopic FMT was scored using the Mayo endoscopic subscore for UC - rCDI recipients [38] 148 and the simple endoscopic score for CD - rCDI (SES-CD) [39].

149

150 **Fig 2. CONSORT 2010 flow diagram.**

151

152 **Dietary information**

The recipients and donors were asked to record daily dietary intake on the Stony Brook University Medical Center Department of Pediatrics Food Diary/Calorie Count for 7 days prior to the collection of each stool sample. Patients were grouped into three categories on review of their dietary logs and interviews: 1.) animal protein-meat (mostly standard "western" diet); 2.) vegetarian (predominantly plant based but animal protein from eggs and dairy); and 3.) plant based protein source (vegan but could include honey).

159 Fecal calprotectin analysis

160 Levels of the neutrophilic fecal calprotectin protein, a clinical marker of gut mucosal inflammation,

161 was measured using the PhiCal Test (Calpro AS, Norway) enzyme-linked immunosorbent assay

162 (ELISA) following the manufacturer's recommended protocol as previously described [36].

163 **16S rRNA sequence analysis**

164 16S rRNA sequencing targeting the V3V4 variable region of the 16S rRNA gene: primers 338F

165 (5' ACTCCTACGGGAGGCAGCAG) and 806R (5' GGACTACHVGGGTWTCTAAT) was carried

166 out by the Frank laboratory at the U of Colorado as previously described [36]. All de-multiplexed,

167 paired-end 16S rRNA sequencing data along with the metadata were deposited into the NCBI

168 Sequence Read Archive under BioProject accession number PRJNA739170.

169 BA metabolomics analysis by liquid chromatography-mass spectrometry (LC-MS).

170 Human stool samples (~400 mg) were weighed into 7 mL bead tubes containing 1.4 mm ceramic 171 beads (Omni International) and extracted using 80% methanol containing deuterated labeled 172 internal standards [ISTDS: chenodeoxycholic acid-d4 (CDCA-d4),taurochenodeoxycholic acid-173 d4 (T-CDCA-d4), glycochenodeoxycholic acid-d4 (G-CDCA-d4), cholic acid-d4 (CA-d4), 174 taurocholic acid-d4 (T-CA-d4), glycocholic acid-d4 (G-CA-d4), deoxycholic acid-d4 (DCA-d4), 175 taurodeoxycholic acid-d4 (T-DCA-d4), glycodeoxycholic acid-d4 (G-DCA-d4), lithocholic acid-d4 176 (LCA-d4), tauro-lithocholic acid (T-LCA-d4), glycolithocholic acid-d4 (G-LCA-d4), ursodeoxycholic 177 acid-d4 (UDCA-d4), T-UDCA-d4, and β -muricholic acid-d5 (β -MCA-d5)] for a final concentration 178 of 100 mg/mL (see S2 Table). The ISTDs were purchased from Cambridge Isotope Laboratories 179 (Tewksbury, MA); except β -MCA-d5 that was purchased from Isosciences (Ambler, 180 PA). Samples were homogenized using a Bead Ruptor (Omni International, Kennesaw, GA) at 6 181 m/s for 6 cycles of 30 s at 4°C, then stored at -80°C overnight. Stool extracts were then vortexed, 182 transferred to 5 mL Eppendorf tubes, centrifuged at 20,000 x g for 20 min at 4°C and diluted with 183 Milli-Q water to 50% methanol content. Samples were then filtered using 96-well Acroprep 184 Advance plates (Pall Corporation, Port Washington, NY) and analyzed by LC-MS analysis BA 185 were separated using two chromatographic methods: 1.) Agilent 1290 Infinity LC system coupled

186 to an Agilent 6550 iFunnel Q-TOF with a 1.6 µm, 2.1 × 50 mm CORTECS T3 column (Waters) 187 and 2.) Agilent 1290 Infinity II LC system coupled to an Agilent 6546 Q-TOF with a 1.7 µm, 2.1 × 188 150 mm ACQUITY UPLC BEH Shield RP18 column (Waters). Active reference mass correction 189 was used according to the manufacturer's instructions. Mobile phase A was 0.1% formic acid in 190 water, mobile phase B was 0.1% formic acid in acetone. LC gradient for Method 1: 30% B to 65% 191 B over 14 min (flow rate: 0.4 mL/min) and for Method 2: 30% B to 80% B over 30 min (flow rate: 192 0.3 mL/min). Both methods ended with 100% B for 2 min and re-equilibration for 6 min. Acquisition 193 was from m/z 50-1,700 at 2 Hz. Mass spectrometer source conditions for both methods: gas 194 temperature: 240°C; drying gas flow: 10 L/min; nebulizer: 60 psi; sheath gas temperature and 195 flow: 400°C and 10 L/min, respectively. The voltages used were: fragmentor: 175 V; skimmer: 45 196 V; capillary: 4000 V; and nozzle: 500 V. Sample injection volume was 5 µL, and data was collected 197 in negative ionization mode. A pooled sample was injected regularly throughout the batch to 198 monitor instrument performance. Data files were converted to Agilent SureMass format and 199 analyzed in Agilent MassHunter Quantitative Analysis software (version 10.1, Agilent 200 Technologies, Santa Clara, CA). Concentrations were estimated by referencing peak areas to a 201 specified ISTDs of known concentration (S2 Table), except for sulfated-BAs and 3-oxo-LCA, 202 which used an external calibration curve.

203 Shotgun DNA metagenomics analysis

204 Shotgun DNA metagenomics sequencing was carried out on fecal DNA samples at Novogene 205 Corp Inc. (Beijing, China). DNA samples were assessed using Qubit Fluorimeter while agarose 206 gel electrophoresis was carried out to check for DNA degradation. The NEBNext UltraTMII DNA 207 Library PrepKit for Illumina® (Ipswich, MA) was used to prepare the sequencing libraries 208 according to the manufacturer's protocols and Illumina 150 bp paired end (PE150) sequencing 209 was conducted on the HiSeqX instruments with a targeted depth of 20 million. Quality filtering 210 (e.g., removal of adapters, human sequences, low-quality sequences) was conducted using 211 KneadData version 5.1 (http://huttenhower.sph.harvard.edu/kneaddata) as previously described

[33]. All de-multiplexed, paired-end shotgun DNA metagenomic sequencing data along with the metadata were deposited into the Sequence Read Archive under BioProject accession number PRJNA739170. Reads corresponding to BA metabolizing enzymes were identified by a translated search with DIAMOND [40] and a manually curated protein sequence database (see S3 Table), respectively at two threshold levels: 1.) 80% identity over 80% sequence and 2.) 50% identity over 80% sequence. Reads corresponding to antibiotic resistance genes were identified using the Comprehensive Antimicrobial Resistance Database (CARD).

219 Statistical analysis

220 Baseline patient characteristics were compared between the donors and the four groups of FMT 221 recipients Alpha diversity indices (e.g. Chao1, Shannon complexity H, Shannon Evenness 222 H/Hmax) were calculated inferred through 1000 replicate resamplings using Explicet [41], and β -223 diversity (Bray-Curtis distances) were calculated between the recipient samples and their paired 224 donor samples as previously described [36]. The Sørensen similarity score is defined as 1- Bray-225 Curtis index, and 0.6 was selected as the threshold level for successful implantation of the donor 226 microbiota [27]. P-values less than 0.05 were considered as statistically significant. Because 227 many of the 385 operational taxonomic units (OTUs) exhibited zero counts across multiple 228 libraries, generalized linear mixed models (GLMM) or generalized estimating equation (GEE) 229 models were used to analyze 108 OTUs after eliminating OTUs with an average relative 230 abundance of < 0.001% in the donor and recipient pre-FMT samples, and after discarding OTUs 231 where more than 75% of the samples had a zero count. To compare the relative abundance of 232 each OTU between donors and recipient time points before and after FMT (pre-transplant, 1 week 233 post-FMT, 3 months post-FMT) within each disease group (rCDI - IBD, rCDI + IBD, UC - rCDI, 234 CD - rCDI), GLMMs or GEEs were used by taking the actual counts of each OTU as the outcomes 235 that were assumed to follow a negative binomial distribution [36]. The log-transformed overall 236 sequence count for each individual at each time point was considered as an offset. Two-way 237 interaction terms (Group*FMT) were used to estimate the difference between the time points

238 within a specific disease group. Possible covariance structures to model correlation among 239 longitudinal measurement from the same patient and measurement in the corresponding donor 240 were unstructured (UN) and compound symmetry (CS). In GEE, the dependence structure was 241 chosen based on Quasi Information Criteria (QIC). Pair-wise P-values were based on the T-test 242 for GLMM, and the Z-test for GEE. The P-values were adjusted for multiple comparisons by the 243 Bonferroni correction (P threshold = 0.05/number of multiple comparison) or by the Benjamini-244 Hochberg method (false discovery rate or FDR < 0.05) as described further in the text. Kruskal-245 Wallis tests were used to compare BA levels between donor and four pre-FMT recipient groups. 246 Post-hoc Dunn's tests with Benjamini-Hochberg adjustments were then performed in comparison 247 of recipient groups and donor. Linear mixed models were used to estimate the pairwise BA 248 differences between pre-FMT recipient and donor as well as response post-FMT in each disease 249 group. UN or CS covariance structures were selected to model the correlation among longitudinal 250 measurements from the same patient and his/her corresponding donor based on (Aikaike 251 Information Criteria (AIC). Log-transformation was applied if the normality assumption was not 252 satisfied. If log-transformation was performed, pre-FMT recipient/donor ratios were shown; 253 otherwise, donor- pre-FMT recipient differences were shown. Kruskal-Wallis tests were also used 254 to compare bacterial gene abundances (cpm) at 80% identity between donor and four pre-FMT 255 recipient groups. Estimated correlation coefficients were generated from linear mixed models 256 treating FMT groups as clustering effect, in order to assess the correlations between bacterial 257 gene abundances (cpm). Log transformation was applied to bacterial gene abundances if 258 normality assumption was not met. All analysis was performed in SAS 9.4 (SAS institute Inc., 259 Cary, NC) and R 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria).

260

261 Results

262 Patient characteristics of FMT donors and recipient samples analyzed.

263 The characteristics of the 55 recipient/donor pairs, segregated according to donors and the four 264 groups of recipients, are summarized in Table 1. The median age in the rCDI – IBD group was 265 significantly higher than the donor and the other three recipient groups. Significant differences in 266 the proportion of males between groups was also observed, being particularly high in the UC -267 rCDI and CD - rCDI groups. Donors and recipients in all groups had predominantly 268 White/European Ancestry (EA) and no Black/African Ancestry (AA) subjects. While only a 269 minority of patients were current smokers, there were differences in the proportion of former 270 smokers and never smokers between groups. All of the rCDI recipient groups received antibiotics 271 within a month prior to the FMT in order to prevent recurrence of CDI, whereas none of the donors 272 (within 3 months of donating the stool sample), UC - rCDI or CD - rCDI recipients (within one 273 month of undergoing FMT) received antibiotics. 20% of rCDI - IBD recipients and 56-62% of the 274 IBD recipients with or without rCDI had abnormal fecal calprotectin levels (> 120 $\mu q/q$). Of the 43 275 donors measured, only two had borderline values (> 50 $\mu q/q$, < 120 $\mu q/q$) and the rest had normal 276 values ($\leq 50 \mu g/g$).

277

Table 1. Baseline characteristics of donors and the four groups of FMT recipients. The median values and interquartile range (IQR) are listed for each group. Fecal calprotectin \leq 50 $\mu g/g$, normal; 50.1-120 $\mu g/g$, borderline; > 120 $\mu g/g$, abnormal.

Variable	Donor	Group 1	Group 2	Group 3	Group 4
		rCDI - IBD	rCDI + IBD	UC - rCDI	CD - rCDI
	n = 55	n = 27	n = 8	n = 11	n = 9
Age (y) ± IQR	43 ± 25	66 ± 21	37 ± 29	37 ± 18	18 ± 4
Sex n (%)					
Males	23 (42%)	8 (30%)	3 (38%)	6 (54%)	8 (89%)
Race n (%)					

White/EA	52 (95%)	27 (100%)	8 (100%)	10 (82%)	7 (78%)
Black/AA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Asian	3 (5%)	0 (0%)	0 (0%)	2 (18%)	2 (22%)
Ethnicity					
Hispanic n (%)	8 (15%)	2 (7%)	2 (25%)	2 (18%)	0 (0%)
Smoking n (%)					
Current	5 (9%)	4 (15%)	0 (0%)	1 (9%)	0 (0%)
Former	9 (16%)	13 (48%)	2 (25%)	4 (36%)	1 (11%)
Never	41 (75%)	10 (37%)	6 (75%)	6 (55%)	8 (89%)
Body mass index (BMI)					
kg/m² ± IQR	23.8 ± 7	27.1 ± 7.6	23 ± 7	27 ± 9	20 ± 5
Diet n (%)					
Meat	49 (89%)	27 (100%)	8 (100%)	10 (91%)	8 (89%)
Vegetarian (dairy)	5 (9%)	0 (0%)	0 (0%)	1 (9%)	1 (11%)
Plant based	1 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Antibiotics n (%)					
within 3 month	0 (0%)	27 (100%)	8 (100%)	1 (9%)	0 (0%)
IBD medications n (%)					
5-ASA	0 (0%)	0 (0%)	6 (75%)	7 (64%)	5 (56%)
Steroids	0 (0%)	0 (0%)	1 (12%)	4 (36%)	3 (33%)
Immunomodulators	0 (0%)	0 (0%)	5 (62%)	4 (36%)	4 (44%)
Biologics	0 (0%)	0 (0%)	2 (25%)	4 (36%)	4 (44%)
None	55 (100%)	27 (100%)	1 (12%)	1 (12%)	2 (22%)
Fecal calprotectin n (%)					
Abnormal	0 (0%)	6 (22%)	5 (62%)	7 (64%)	5 (56%)

Borderline	2 (4%)	6 (22%)	3 (38%)	2 (18%)	0 (0%)
Normal	41 (74%)	15 (56%)	0 (0%)	2 (18%)	3 (33%)
Missing	12 (22%)	0 (0%)	0 (0%)	0 (0%)	1 (11%)

281

282 Clinical outcomes for the four recipient groups.

The primary endpoint for rCDI was defined as no further rCDI at 12 months after FMT in rCDI recipients with or without IBD. FMT was 92% effective in preventing rCDI in the rCDI - IBD group and 75% effective in the rCDI + IBD group. These results compare favorably to the previously reported 91% efficacy in in donor FMT compared to 67% effectiveness of the sham FMT [2] and previously reported uncontrolled FMT studies performed in rCDI patients with IBD [10-15].

The primary endpoint for gut inflammation as measured by fecal calprotectin levels was one week after FMT for all recipients because many IBD patients were prescribed changes in their medications between one week and 3 month time points. We did not observe a clear effect of a single colonoscopic FMT on gut inflammation in IBD recipients as measured by decreased fecal calprotectin.

294 Serious adverse events (SAEs) were reported in six patients as listed in S4-S7 Tables. 295 The SAEs in three rCDI – IBD recipients and one UC - rCDI recipient, were deemed unrelated to 296 the FMT procedure on review by the Data Safety Monitoring Board. The remaining two SAEs 297 observed in one rCDI + IBD (CD) and one CD – rCDI recipient could have reflected progression 298 of their underlying disease but could also have been related to the procedure, since flares have 299 been previously reported in other IBD patients post FMT [12].

300 16S rRNA gene sequencing results.

16S rRNA gene profiling of fecal bacterial communities was accomplished for 165 fecal
 DNA samples, collected from 43 of 55 donors, 18 of 27 rCDI - IBD recipients, 8 of 8 rCDI + IBD
 recipients, 9 of 11 UC - rCDI recipients and 8 of 9 CD - rCDI recipients.

Linear mixed models comparing the ShannonH α -diversity index between donor and recipient pairs in each of the four groups (Fig 3) revealed significant differences between the donor group and both the rCDI - IBD (*P* = 0.0001) and rCDI + IBD (p <0.0001) groups at baseline (Pre-FMT), with resolution of these differences at the 1 week and three month time points. In contrast, differences in α -diversity between donor and recipient did not reach significance for either the UC - rCDI or CD - rCDI groups.

310

Fig 3. α-diversity (ShannonH) in the donor and four recipient groups Pre-FMT, 1 week Post FMT and 3 month Post-FMT.

313

314 A recent report of a clinical FMT trial in CD patients [27] set successful implantation of 315 donor stools as achieving a Sørensen similarity index > 0.6 (the maximum value of 1 indicates 316 identical communities) between paired donors and recipients. We therefore adopted the same 317 endpoint in analyzing our 16S rRNA gene sequencing results. The pre-FMT Sørensen similarity 318 indices were below the endpoint in all of the rCDI recipients with and without IBD (Table 2), with 319 overall increases in these indices post-FMT. Individually the endpoint of > 0.6 was reached post 320 FMT in 73% of the rCDI recipients. Among the IBD - rCDI groups prior to FMT, 5 of 9 (56%) UC -321 rCDI recipients and 5 of 7 (71%) CD - rCDI recipients had donor-recipient pre-FMT Sørensen 322 similarity indices below the endpoint. Three of these recipients had evidence of active disease 323 based on their initial fecal calprotectin level and endoscopic score (Mayo or SES-CD). Three of 324 the 5 UC - rCDI donor-recipient pairs and 3 of 5 5 CD - rCDI recipients reached the endpoint 325 post-FMT at either the 1 week and/or 3 month time point. However, achieving this endpoint was 326 not necessarily associated with reduction of gut inflammation measured using fecal calprotectin

- 327 levels. Note that none of the CD recipients in the previously published sham controlled FMT study
- 328 of CD recipients achieved a Sørensen similarity index > 0.6 at the 6 week post-FMT time point
- 329 [27].
- 330
- Table 2. Median Sørensen similarity index ± IQR between paired donors and recipients at

552 I IC-I WIL, I WEEK POSLI WIL AND 5 INDITUIS POSLI W	332	Pre-FMT,	1 week	post FMT	and 3	months	post FM
---	-----	----------	--------	----------	-------	--------	---------

Group	Pre-FMT	1 week Post-FMT	3 month Post-FMT
rCDI - IBD	0.26 ± 0.28	0.65 ± 0.09	0.66 ± 0.16
(n =18)			(3 missing)
rCDI + IBD	0.08 ± 0.26	0.55 ± 0.28	0.49 ± 0.15
(n = 8)			
UC - rCDI	0.54 ± 0.27	0.62 ± 0.14	0.61 ± 0.22
(n = 9)			(3 missing)
CD - rCDI	0.52 ± 0.14	0.62 ± 0.19	0.63 ± 0.17
(n = 8)	(1 missing)		

333

We next analyzed how abundances of individual bacterial taxa (from 16S rRNA gene sequencing) differed between recipient groups (rCDI – IBD, rCDI + IBD, UC – rCDI, CD – rCDI), and healthy donors as previously described [36]. Pairwise comparisons of the estimated recipient/donor ratios were then carried out. 72 OTUs demonstrating significant estimated pre-FMT recipient/donor ratios with 95%CI in at least one of the four recipient groups with a FDR (q) <0.05 are listed in S7 – S14 Tables and selected taxa are highlighted in Table 3.

340

Table 3. Significant (FDR <0.05) estimated pre-FMT recipient/donor ratios (95% Cl) of the relative abundances of selected genus level OTUs for each of the four recipient groups.

343	See also S7 – S14 Tables). A ratio > 1 indicates ↑ relative abundance in recipient pre-FMT
344	compared to donor samples. A ratio of < 1 indicated \downarrow relative abundance in pre-FMT samples
345	compared to donor samples. The 95% CI are shown in parenthesis. Only the estimated ratios
346	with an FDR < 0.05 are listed. The * indicates those OTUs that also had significant estimated
347	ratios of post-FMT/pre-FMT relative abundances at with 1 week and/ or 3 month time point,
348	indicating that FMT had a significant effect.

ΟΤυ	rCDI - IBD	rCDI + IBD	UC - rCDI	CD - rCDI
Actinomyces				4.15*
				(1.71,10.04)
Collinsella	0.04*	0.001*		0.34*
	(0.006,0.22)	(0,0.002)		(0.18,0.62)
Bacteroides	0.15*	0.08		
	(0.06,0.37)	(0.01,0.63)		
Prevotella		0.03*		
		(0.005,0.19)		
Faecalibacterium	0.004*	0.003*		
	(0.002,0.007)	(0.002,0.004)		
Ruminococcus	0.02*	0.02* (0.003,0.07)	0.37	
	(0.003,0.14)		(0.23,0.61)	
Dorea	0.003*	0.003*		
	(0.001,0.008)	(0.001,0.005)		
Enterococcus	147.86*		39.72	17.23*
	(32.5,673.0)		(12.4,127.0)	(5.33,55.7)
Lactobacillus	151.55*	891.53*	94.61*	
	(40.7,564.4)	(300.8,2642.3)	(29.7,301.4)	

Escherichia-	15.59*	43.75*	76.65
Shigella	(4.29,56.7)	(12.1,158.7)	(9.39,625.7)
Fusobacterium	640.51*	3209.89*	13.51*
	(147.2,2786.8)	(875.9,11763.4)	(1.88,96.8)

349

350 The expanded dataset with 16S rRNA gene sequence data generated from 7 additional 351 recipients in the rCDI - IBD group, confirmed 47 of 51 OTUs previously reported [36] with a 352 significant estimated pre-FMT recipient/donor ratio. The expanded dataset for the rCDI + IBD 353 recipients generated from 5 additional recipients, including 3 with underlying CD [36] confirmed 354 54 of 71 OTUs previously reported with a significant estimated pre-FMT recipient/donor ratio. The 355 expanded dataset for the UC -rCDI recipients generated from 4 additional recipients [36]. 356 confirmed only 15 of 29 OTUs previously reported with a significant estimated pre-FMT 357 recipient/donor ratio. Increased recipient/donor ratios for Bacilli, Proteobacteria and Fusobacteria 358 OTUs were among those confirmed for the UC - rCDI group. The results of 16S rRNA gene 359 sequence analysis for the fourth recipient group, CD - rCDI, detected significant estimated pre-360 FMT recipient/donor ratios in 27 OTUs, including decreased ratios in Actinobacteria, Bacteroides 361 and Ruminococcaceae OTUs and increased ratios in Bacilli, Gamma-proteobacteria and 362 Fusobacteria OTUs.

363 **Quantitative targeted analysis of BA metabolites.**

We initially observed relative peak differences in BA on a subset of samples, which suggested that secondary BA metabolites were reduced not only in a subset of the rCDI – IBD and rCDI + IBD groups [36], but also in the CD - rCDI group (data not shown). To further pursue these findings, 23 bile acid metabolites including secondary BA epimers (see Fig 4), which have recently been implicated in regulating immune function [30-32], were quantitatively measured in 212 samples in 55 donor/recipient pairs by targeted LC-MS (S15 Table). Prior to FMT, 19 BA metabolites differed significantly from the donor group by a post-hoc Dunns test with Benjamini-

371 Hochberg adjustments (see S16 Table). The unconjugated secondary BA, lithocholic acid (LCA) 372 and deoxycholic acid (DCA), were the predominant metabolites in the healthy donors, but low 373 levels of secondary bile acid epimers, 3-oxo-lithocholic acid (3-oxo-LCA), iso-lithocholic acid (iso-374 LCA) and isoallo-lithocholic acid (isoallo-LCA) were also detected (see Fig 4 and 5). In contrast, 375 the unconjugated primary BA, chenodeoxycholic acid (CDCA) and cholic acid (CA), were the 376 predominant metabolites detected in the rCDI-IBD recipients, with significant reduction of 377 secondary BA and epimers. For the rCDI + IBD recipients, in addition to the increased levels of 378 primary unconjugated BA (CDCA and CA) and reduced secondary BA levels, increased levels of 379 conjugated primary BA, taurocholic acid (T-CA), glycochenodeoxycholic acid (G-CDCA) and 380 glycocholic acid (G-CA), were also observed. The BA metabolite profile for the UC - rCDI 381 recipients was very similar to that of the healthy donors, whereas a reduction of unconjugated 382 secondary BA and epimers was observed for the CD - rCDI recipients (Fig 5).

383

384 Fig 4. BA metabolic pathways. Chenodeoxycholate (CDCA) is synthesized in the liver and 385 conjugated with taurine and glycine before being secreted to the small intestine. 386 Taurochenodeoxycholate (T-CDCA) and glycochenodeoxycholate (G-CDCA) are then 387 deamidated to chenodeoxycholate (CDCA) (1) by gut bacteria containing the bile salt hydrolase 388 (BSH) enzyme. CDCA can be further 7α -dehydroxylated to lithocholic acid (LCA) (2) by the 389 concerted action of 6 enzymes in the bai operon (baiA2, baiB, baiCD, baiE, baiF, and baiH). LCA 390 can be further transformed to 3-oxo-LCA (3) by action of 3α -hydroxysteroid dehydrogenases (3α -391 HSDH), and transformed to iso-LCA (4) if the ketone at position C3 of 3-oxo-LCA is reduced to a 392 3β-alcohol, by action of 3β-HSDH, or (5) isoallo-LCA by the concerted action of $5\beta/\alpha$ -reductases 393 and 3β-HSDH.

394

Fig 5. Fecal BA metabolites in donors and the four recipient groups at baseline. The total
 median ± IQR concentrations of conjugated primary BAs (T-CA, G-CDCA, G-CA), unconjugated

397 primary BAs (CDCA, CA), unconjugated secondary BAs (LCA, DCA) and unconjugated 398 secondary BA epimers implicated in immune regulation (3-oxo-LCA, iso-LCA, isoallo-LCA) are 399 shown.

400

401 In order to measure the effect of FMT on the BA metabolites, fitted linear mixed models 402 with pairwise comparisons were conducted for 16 BA metabolites that required log transformation 403 to measure the estimated pre-FMT recipient donor ratios and response post-FMT (see Table 404 4). Fitted linear mixed models with pair wise comparisons were conducted for the remaining 3 405 BA metabolites that did not require log transformation to measure the estimated donor-pre-FMT recipient differences and response post-FMT (see Table 5). These results indicate that FMT has 406 407 a significant effect on restoring secondary BA metabolite levels in rCDI - IBD, rCDI + IBD and CD 408 - rCDI recipients.

409

410 Table 4. Estimated pre-FMT recipient/donor BA ratios (95% Cl) in the four recipient groups.

411 A ratio > 1 indicates \uparrow recipient pre-FMT BA level compared to donor. A ratio of < 1 indicated \downarrow 412 recipient pre-FMT level compared to donor. Only the estimated ratios with an unadjusted p-value 413 < 0.05 are listed. The * indicates those BA that also had a significant estimated ratios of post-414 FMT/pre-FMT ratios at the 1 week and/or 3 month time point, indicating that FMT had a significant 415 effect.

BA	rCDI – IBD	rCDI + IBD	UC – rCDI	CD – rCDI
Primary conjugated				
T-CA		29*		
		(3,333)		
G-CDCA	5*	21*		
	(2,12)	(4,100)		

G-CA	6*	33*	
	(2,20)	(4,250)	
Primary unconjugated			
CDCA	6*		13
	(1.4,29)		(1.03,143)
CA	24*		26
	(7,77)		(4,200)
CDCA-3-sulfate	43*		12
	(14,143)		(2,77)
CA-3-sulfate	15*		
	(6,38)		
Secondary conjugated			
G-DCA	0.2*		0.2
	(0.07,0.4)		(0.05,0.85)
Secondary unconjugated			
iso-CDCA	3*		20*
	(1.01,8)		(4,111)
iso-LCA	0.008*	0.27*	0.03*
	(0.003,0.027)	(0.004,0.207)	(0.005,0.22)
isoallo-LCA	0.06*		0.11
	(0.03,0.13)		(0.03,0.41)
3-oxo-DCA	0.014*	0.047*	0.04*
	(0.005,0.04)	(0.008,0.29)	(0.008,0.24)
3-oxo-CA	6.6*		9.3
	(2.4,18)		(1.9,48)

3-oxo-LCA	0.016*	0.04*	0.017*
	(0.004, 0.06)	(0.004,0.44)	(0.002,0.15)
3-oxo-CDCA	8.5*		7.4
	(3,23)		(1.4,38)
<u>U</u> CDA-3-sulfate	27*		
	(9,77)		

416

417

Table 5. Estimated donor – pre-FMT recipient BA differences (*pmol/g* wet weight stool or μ M, 95% Cl) in the four recipient groups. A positive difference indicates that the donor secondary unconjugated BA level was greater than the pre-FMT recipient level. The (*) indicates significant paired end differences between the pre-FMT and the 1 week and/or 3 month post-FMT (p-value < 0.05).

Secondary unconjugated BA	rCDI – IBD	rCDI + IBD	UC – rCDI	CD – rCDI
DCA	6204*	3749		
	(4444,7694)	(685,6813)		
LCA	10596*	7968		5621
	(7785,13408)	(3063,12873)		(996,10246)
iso-DCA	1871*	1314		715*
	(1491,2251)	(656,1972)		(94,1335)

423

424 Shotgun DNA metagenomics data

425 Shotgun DNA metagenomics sequencing was performed on samples from 32 426 donor/recipient pairs (118 samples). After removing human sequences, an average of 427 21,513,616 sequences (range 220,028 - 59,164,588) was obtained for each sample. We initially 428 screened the samples for extended-spectrum beta lactamase (ESBL) genes given the recent

report of a fatality from transmission of an ESBL producing *E. coli* from donor to recipient (42). OXA-137, an ESBL gene was detected in one rCDI no IBD recipient prior to the procedure and at one week post–FMT but not at three months post-FMT [43]. No ESBL genes were detected in the 32 donor stools sequenced.

433 Conversion of unconjugated primary BA to secondary BA (e.g. CA to DCA, and CDCA to 434 LCA), is mediated by enzymes encoded by 8 genes in the BA-inducible (bai) operon (see Fig 4), 435 which is carried by a small population of commensal bacteria, including *Clostridium scindens*, 436 Clostridium hylemonae, Clostridium hiranonis [29]. It has been reported that fecal baiCD gene 437 copy numbers is negatively correlated with CDI in humans [44], although concomitant presence 438 of C. scindens and C. difficile has been reported in a metagenomics study [45]. The abundances 439 of the *baiCD* gene, (coding the 5 β -reductase), and the *baiE* gene, (which encodes the 7 α -440 dehydroxylase), were estimated by translated searches of the shotgun metagenomics sequence 441 data with DIAMOND [40] using the C. scindens protein sequence for the baiE and baiCD genes 442 at two threshold levels: 1.) 80% identity over 80% sequence and 2.) 50% identity over 80% 443 sequence to calculate the counts per million (cpm). There were high correlations between the 444 baiE cpm and baiCD cpm at both homology thresholds, consistent with both genes being in the 445 same operon (see S17 Table). Lowering the threshold for identity from 80% to 50% markedly 446 increased the *baiCD* gene cpm, but had only a modest effect on the *baiE* gene cpm. This 447 suggested that a much larger number of bacterial genes, which may include genes not involved 448 in the BA metabolism pathways, share protein sequence homology with the baiCD protein than 449 the *baiE* encoded 7α -dehydroxylase.

Previous studies have reported a correlation between *baiCD* gene counts measured using degenerate PCR primers and rCDI [28,43]. Using these degenerate primers, we observed multiple amplicons with a large range of sizes after analyzing the PCR reactions by gel electrophoresis, but only observed single amplicon bands using specific *C. scindens* and *C.*

454 *hiranonis* primers. Consistent with previous studies, a higher proportion of rCDI \pm IBD recipients 455 lacked detectable *baiE* cpm compared to donors (see Fig 6).

456

457 Fig 6. Detection of *baiE* gene (50% identity DIAMOND search of shotgun metagenomics 458 data) in donors and the 4 recipient groups at baseline.

459

460 In contrast to the limited number of baiE 7a-dehydroxylase protein sequences in relatively 461 few strains, there are hundreds of bacterial bile salt hydrolase (BSH) protein sequences 462 distributed among 591 intestinal bacterial strains within 119 genera in the human microbiome 463 [46]. Song et al. [46] categorized these sequences into 8 BSH phylotypes (BSH-T0 to BSH-464 T7). The custom DIAMOND search used in this study, included 31 BSH protein sequences from 465 eight BSH phylotypes (S1 Table). The abundance of each BSH phylotype was calculated as the 466 sum of the individual BSH protein sequence cpms at 80% identity. As shown in Fig 7, the pattern 467 of BSH phylotypes for the donors, UC-rCDI and CD-rCDI observed in this study was similar to the 468 pattern described for the US population by Song et al. [46], with a relative prominence of the BSH-469 T6 phylotype. In contrast, the relative abundances of all BSH phylotypes were reduced in the rCDI 470 - IBD and rCDI + IBD recipients prior to FMT.

471

472 Fig 7. Median BSH phylotype abundances ± IQR (80% identity DIAMOND search of shotgun 473 metagenomics data) in donors and 4 recipient groups at baseline.

474

The 3- α - and 3- β - hydroxysteroid dehydrogenases (HSDHs) from *R. gnavus* and *E. lenta*, metabolize LCA to 3-oxo-LCA and then to iso-LCA (see Fig 4), which exhibit *in vitro* activity on Tcell regulation [30-32]. Not surprisingly, the correlations were significant between the gene counts of HSDHs (80% identity) from the same taxa, however the correlation between the 3 β -HSDH between *R. gnavus* and *E. lenta* was not significant (see S18 Table). No significant differences in

480 the median R. gnavus 3α -HSDH cpm or 3β -HSDH cpm were observed between the donors and 481 the pre-FMT levels of the four recipient groups, although decreased estimated pre-FMT 482 recipient/donor ratios for Ruminococcus denus rRNA dene was observed in the rCDI - IBD and 483 rCDI + IBD groups (see Table 3). A significant difference was observed for median *E. lenta* β-484 HSDH cpms between the donors and the Pre-FMT levels of the four recipient groups (P = 0.0117), 485 with significant difference between the rCDI - IBD and the UC - rCDI groups (P = 0.0184), and 486 between the rCDI + IBD and UC - rCDI groups (P = 0.0200). Similarly, a significant difference 487 was also observed for median *E. lenta* α -*HSDH* cpms between the donors and the pre-FMT levels 488 of the four recipient groups (P = 0.0065), with significant difference between the rCDI - IBD and 489 the UC - rCDI groups (P = 0.0252), and between the rCDI + IBD and UC - rCDI groups (P =490 0.0157).

491 Because B. dorei has been reported to convert iso-LCA to isoallo-LCA, a DIAMOND 492 search was conducted for the putative *B. dorei* 5 β -reductase, 5 α -reductase and 3 β -HSDH 493 enzymes identified by BLAST searches reported by Li et al. [32]. All three of these protein 494 sequences are significantly correlated with each other (see S19 Table). The median cpms for 495 each of these candidate genes were significantly decreased in the rCDI + IBD group compared 496 to donors (P = 0.0003, 0.0003, <.0001 for 3 β -HSDH, 5 β -reductase and 5 α -reductase respectively) 497 and the UC - rCDI groups (P = 0.0076, 0.0059, 0.0056 for 3 β -HSDH, 5 β -reductase and 5 α -498 reductase respectively) and decreased in the rCDI - IBD groups compared to donors (P = 0.0002, 499 0.0007, <0.0001 for 3β-HSDH, 5β-reductase and 5 α -reductase respectively) and the UC - rCDI 500 groups (P = 0.0144, 0.0202, 0.0167 for 3 β -HSDH, 5 β -reductase and 5 α -reductase 501 respectively). This is consistent with the marked decrease in the estimated pre-FMT recipient 502 donor ratios for the Bacteroides genus rRNA gene in the rCDI - IBD and rCDI + IBD groups (see 503 Table 3).

504 In order to integrate the shotgun metagenomics data with the BA metabolite data, we 505 measured the correlation between the abundances of the BA metabolizing genes (cpms) and

506 fecal BA levels using linear mixed models, which clustered values from each FMT group, to 507 calculate the estimated coefficient and 95% confidence interval (CI) (see Tables 6 and 7). Log 508 transformation was applied if the normality assumption was not satisfied. As shown in Table 6. 509 significant negative relationships between the baiE gene abundance (cpm) were observed for 510 fecal chenodeoxycholic acid and cholic acid levels with negative estimated coefficients and p-511 values < 0.05. Significant positive relationships between the baiE gene abundance were 512 observed for fecal secondary BA (DCA and LCA) levels with positive estimated coefficients and 513 p-values < 0.05. Significant positive relationships between the *baiE* gene abundance were also 514 observed for fecal secondary BA epimer, (iso-LCA acid and isoallo-LCA) and the secondary BA 515 intermediate (3-oxo-LCA) levels. No significant correlation was observed between any of the four 516 HSDHs and either 3-ox-LCA or iso-LCA levels. No significant relationships were observed 517 between the gene counts for any of the three candidate *B. dorea* enzymes (5 β -reductase, 5 α -518 reductase and 3β -HSDH) and fecal isoallo-LCA levels, which is present in very low levels across 519 donors and all four recipient groups. Taken together these results suggest that the baiE encoded 520 7α -hydroxylase step may be also rate limiting for the generation of the secondary BA epimers 521 implicated in immunomodulation.

522

523 Table 6. Estimated coefficient and 95% CI for selected unconjugated BA for *baiE* cpm (50%

524 identity threshold) in linear mixed models treating FMT group as clustering effect. *

525 indicates that the value was log-transformed, since the normality assumption was not satisfied.

Unconjugated BA	Estimated coefficient (95% CI)	P-value
primary		
CDCA*	-0.57 (-0.84, -0.29)	< .0001
CA*	-0.64 (-0.92, -0.35)	< .0001

<u>secondary</u>

DCA	455.63 (27.48, 883.77)	0.0373
LCA	1133.55 (329.45, 1937.65)	0.0063
secondary intermediate		
3-oxo-LCA*	0.57 (0.28, 0.86)	0.0002
secondary epimer		
iso-LCA	161.14 (36.43, 285.86)	0.0120
isoallo-LCA*	0.37 (0.16, 0.58)	0.0008

526

- 527
- 528 Table 7. Estimated coefficient and 95% Cl for each conjugated primary BA for 7 of the 8

529 BSH phylotype cpm (80 % identity threshold) in linear mixed models treating FMT group

530 **as clustering effect.** * indicates that value was log-transformed.

BSH	Conjugated primary BA	Estimated coefficient	P-value
phylotype		(95% CI)	
BSH-T0*	T-CA	0.0002 (-0.0004, 0.0007)	0.5513
	G-CDCA	-0.0001 (-0.0002.0.00001)	0.0674
	G-CA	-0.00006 (-0.0001, 0.00001)	0.0914
BSH-T1	T-CA	-0.06 (-0.09, -0.02)	0.0064
	G-CDCA	-0.0091 (-0.0161, -0.0021)	0.0123
	G-CA	-0.0096 (-0.0168, -0.0012)	0.0119
BSH-T2*	T-CA	-0.0004 (-0.0009, 0.00004)	0.0739
	G-CDCA	-0.00013 (-0.0002, -0.0001)	0.0006
	G-CA	-0.00014 (-0.0002, -0.0001)	0.0008
BSH-T4*	T-CA	-0.0004(-0.0014, 0.0002)	0.0104
	G-CDCA	-0.00013 (-0.0002, -0.0001)	0.0006

	G-CA	-0.00014 (-0.0002, -0.0001)	0.0008
BSH-T5	T-CA	-0.04 (-0.06, -0.01)	0.0016
	G-CDCA	-0.0052 (-0.0090, -0.0015)	0.0071
	G-CA	-0.0055 (-0.0094, -0.0016)	0.0061
BSH-T6	T-CA	-0.11 (-0.18,-0.04)	0.0035
	G-CDCA	-0.0154 (-0.0278, -0.0029)	0.0162
	G-CA	-0.0164 (-0.0292, -0.0035)	0.0133
BSH-T7	T-CA	-0.05 (-0.07, -0.02)	0.0027
	G-CDCA	-0.0063 (-0.0115, -0.0010)	0.0208
	G-CA	-0.0032 (-0.0057, -0.0007)	0.0135

531

532 Because there were multiple zero counts for BSH-T3 phylotype abundance, this phylotype 533 was excluded from our analysis. BSH-T3 is composed of lactobacillus BSH genes. To correct for 534 multiple comparisons between the remaining 7 BSH phylotype relative abundances (cpm) and 535 the fecal levels of the three conjugated primary BAs, T-CA, G-CDCA and G-CA we applied the 536 Bonferroni correction to set the threshold p-value as 0.05/7 = 0.007. Based on this threshold, we 537 observed significantly negative relationships between BSH-T1, BSH-T5 BSH-T6 and BSH-T7 538 phylotype relative abundances (cpm) and fecal T-CA levels. We observed significantly negative 539 relationships between BSH-T2 and BSH-T4 phylotype abundances (cpm) and fecal G-CDCA and 540 G-CA. These results may be consistent with varying substrate specificities of bacterial BSH 541 enzymes for the taurine and glycine BA conjugates [47,48].

542

543 Discussion

544 We report the results of integrating 16S RNA gene sequencing, shotgun metagenomics 545 sequencing and quantitative BA metabolomic analysis in human stools collected during two

546 colonoscopic single donor fecal microbial FMT clinical trials conducted at SBUMC (2013-547 2020). Our quantitative analysis of primary and secondary BA metabolites in human stool is novel 548 in that secondary BA epimers, which have recently reported to exhibit immunoregulatory activity 549 *in vitro*, were also measured in this study.

550 Decreases in secondary BA have been observed in rCDI and more recently in IBD 551 [28,49]. In this study, we observed a general reduction in the levels of secondary BA including 552 the immunomodulatory derivatives of LCA in the rCDI – IBD, the rCDI + IBD and CD - rCDI groups 553 but not in the UC-rCDI group at baseline prior to transplant. Post FMT, the levels of secondary 554 BA were restored in the rCDI – IBD group and to various extents in the rCDI + IBD and CD – rCDI 555 groups.

556 Parallel estimation of the abundance of secondary BA pathway related protein/gene 557 sequences by polymerase chain reaction assays or shotgun metagenomics sequence analysis 558 and correlating these abundances with metabolite levels could potentially help us predict BA 559 metabolic potential in the human gut [50]. Our approach has been to search the shotgun 560 metagenomics data based on protein sequences of relevant BA-metabolizing enzymes. Because 561 of the knowledge base accumulated on the bacterial metabolism of primary to secondary BA we 562 focused initially on the genes in the bai operon, which is present in only a select number of 563 *Clostridium* species. Based on our analysis supplemented by gualitative PCR assays, we have 564 identified the baiE gene cpm (measured at 50% identity over 80% sequence) as the biomarker 565 associated with a rate-limiting step in the conversion of unconjugated primary BAs to secondary 566 BAs. It is not clear why a significant correlation between the abundances of the other genes, such 567 as *baiCD*, in the bai operon and secondary BA metabolite levels were detected in this study. 568 Based on gel electrophoresis analysis of products of the *baiCD* gene PCR assay, we suspect 569 there may be significant homology between that gene sequence and other genes which are 570 unrelated to the BA transformation pathway.

571 Primary BA must be deconjugated prior to transformation to secondary BA. Consequently 572 loss of BSH activity may also affect secondary BA levels. In contrast to the limited number of taxa 573 involved in the initial conversion of unconjugated primary BA to secondary BA, multiple BSH gene 574 sequences from multiple taxa are implicated in deconjugation of conjugated primary 575 BA. Furthermore some of the homologous gene sequences are pseudogenes that may not 576 contribute to BSH activity [46]. Our approach to estimating BSH activity based on BSH gene 577 abundances was to calculate the sum of selected BSH phylotype gene sequence abundances at 578 80% homology for each of 8 BSH phylotype described by Song et al [46]. This approach yielded 579 donor profiles of BSH phylotype abundances that matched those reported for the US population 580 [46]. BSH phylotype abundances were markedly reduced particularly in the rCDI + IBD recipients 581 prior to FMT compared to healthy donors. Furthermore reduced BSH phylotype abundances 582 were significantly correlated with increased levels of conjugated primary BA levels. These results 583 suggest that IBD patients with rCDI have reduced secondary BA levels due to loss of both 7-a 584 hydroxylase and BSH activities.

585 *B. dorei* 5 β -reductase, 5 α -reductase and 3 β -HSDH gene abundances are reduced in rCDI 586 ± IBD recipients compared to healthy donors. It has been reported that centenarians have 587 microbiomes that are enriched for B. dorei and additional bacterial strain isolates capable of 588 producing isoallo-LCA acid [51]. However it should also be pointed out that LCA levels are also 589 reduced in the rCDI ±IBD recipients along with reduced abundance of the baiE gene encoding 590 the 7-alpha hydroxylase step. The contribution of alterations in the abundances of the 5β -591 reductase, 5α -reductase and 3β -HSDH genes to the production of secondary BA epimers may 592 be reduced simply because more upstream processes drastically reduce levels of secondary BA 593 substrates, such as LCA and DCA.

A major limitation of this study is the small number of subjects in each of the three IBD recipient groups and that these studies were single arm in design. Unfortunately, the COVID pandemic has essentially forced a halt to these clinical trials. Nevertheless, the samples and

multi-omic datasets generated from these samples will continue to provide an important resource
 for characterizing the effect of FMT on microbial function as further progress is made in identifying
 bacterial strains and enzymes involved in the biotransformation of BAs and other metabolites.
 600
 601 Conclusion
 602 Secondary BA metabolite levels, including epimers implicated in immune regulation, are

reduced in rCDI \pm IBD and CD – rCDI recipients compared to donors. Single donor colonoscopic FMT restored many of those levels in these recipients. Integration of shotgun metagenomics and quantitative targeted BA metabolomics analyses indicate that reduction of *baiE* gene abundance is correlated with reduction of secondary BA metabolite levels. In addition BSH phylotype gene abundance is also reduced in particularly rCDI + IBD recipients and is negatively correlated with conjugated primary BA levels.

609

610 Acknowledgements

We want to thank the recipients and donors for participating in this study. We acknowledge the contributions of Drs. Ramona Rajapakse, Michael J Clores, Lionel D'Souza, Alexandra Guillaume in the Division of Gastroenterology and Hepatology, for performing some of the FMT procedures. We acknowledge the biostatistical consultation provided by Junying Wang and the Biostatistics and Data Science Shared Resource at the Stony Brook Cancer Center, Stony Brook University. We thank Dr. Daniel Littman for his helpful comments on the manuscript.

617

618 References

619 1. Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by
620 donated stool transplanted *via* colonoscopy: a case series of 12 patients. J Clin Gastroenterol
621 2010; 44: 562-566.

Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, et al. Effect of fecal microbiota
transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized
trial. Ann Intern Med 2016: 165: 609-616.

3. Mattila E, Uusitalo-Seppälä R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, et al. Fecal
transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile
infection. Gastroenterology 2012; 142: 490-496.

4. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66: 569-

630 **580**.

- 5. Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile
- 632 infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-344.
- 633 6. Ananthakrishnan AN, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease.
- 634 Expert Rev Gastroenterol Hepatol 2010; 4: 589-600.
- 635 7. Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A. Impact of Clostridium
- 636 difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009; 154: 854-858.
- 637 8. Martinelli M, Strisciuglio C, Veres G, Paerregaard A, Pavic AM, Aloi M, et al. Clostridium difficile
- and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN
 study. Inflamm Bowel Dis 2014; 20: 2219-2225.
- 9. Saffouri G, Gupta A, Loftus EV Jr, Baddour LM, Pardi DS, Khanna S. The incidence and
 outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel
 disease. Scand J Gastroenterol 2017; 52: 1240-124.
- 10. Hourigan SK, Chen LA, Grigoryan Z, Laroche G, Weidner M, Sears CL, et al. Microbiome
 changes associated with sustained eradication of Clostridium difficile after single faecal
 microbiota transplantation in children with and without inflammatory bowel disease. Aliment
 Pharmacol Ther 2015; 42: 741-752.

11. Fischer M, Kao D, Kelly C, Kuchipudi A, Jafri SM, Blumenkehl M, Rex D, Mellow M, Kaur N,

648 Sokol H, Cook G, Hamilton MJ, Phelps E, Sipe B, Xu H, et al. Fecal microbiota transplantation is

649 safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with

inflammatory bowel disease. Inflamm Bowel Dis 2016; 22: 2402-2409.

12. Khoruts A, Rank KM, Newman KM, Viskocil K, Vaughn BP, Hamilton MJ, et al. Inflammatory

bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium

difficile infection. Clin Gastroenterol Hepatol 2016; 14: 1433-1438.

13. Khanna S, Vazquez-Baeza Y, González A, Weiss S, Schmidt B, Muñiz-Pedrogo DA, et al.

655 Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile 656 infection affected by underlying inflammatory bowel disease. Microbiome 2017; 5: 55.

14. Tabbaa OM, Aboelsoud MM, Mattar MC. Long-term safety and efficacy of fecal microbiota
transplantation in the treatment of *Clostridium difficile* infection in patients with and without
inflammatory bowel disease: a tertiary care center's experience. Gastroenterology Res 2018; 11:
397-403.

15. Chin SM, Sauk J, Mahabamunuge J, Kaplan JL, Hohmann EL, Khalili H. Fecal microbiota
transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel
disease: a single-center experience. Clin Gastroenterol Hepatol 2017; 15: 597-599.

16. Kump PK, Gröchenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, et al. Alteration
of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients
with chronic active ulcerative colitis. Inflamm Bowel Dis 2013; 19: 2155-2165.

17. Kump P, Wurm P, Gröchenig HP, Wenzl H, Petritsch W, Halwachs B, et al. The taxonomic
composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal
microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther 2018;
47: 67-77.

- 18. Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr, et al. Safety, tolerability, and
- 672 clinical response after fecal transplantation in children and young adults with ulcerative colitis. J
- 673 Pediatr Gastroenterol Nutr 2013; 56: 597-601.
- 19. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal microbiota
- 675 transplantation induces remission in patients with active ulcerative colitis in a randomized
- 676 controlled trial. Gastroenterology 2015; 149: 102-109.
- 20. Mizuno S, Nanki K, Matsuoka K, Saigusa K, Ono K, Arai M, et al. Single fecal microbiota
- 678 transplantation failed to change intestinal microbiota and had limited effectiveness against679 ulcerative colitis in Japanese patients. Intest Res 2017; 15: 68-74.
- 680 21. Nishida A, Imaeda H, Ohno M, Inatomi O, Bamba S, Sugimoto M, et al. Efficacy and safety of
- single fecal microbiota transplantation for Japanese patients with mild to moderately active
 ulcerative colitis. J Gastroenterol 2017; 52: 476-482.
- 683 22. Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, et al.
- 684 Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised
- 685 placebo-controlled trial. Lancet 2017; 389: 1218-1228.
- 686 23. Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, et al. Effect of fecal
- 687 microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized 688 clinical trial. JAMA 2019; 321: 156-164.
- 689 24. Fuentes S, Rossen NG, van der Spek MJ, Hartman JH, Huuskonen L, Korpela K, et al.
- 690 Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota
- 691 transplantation. ISME J 2017; 11: 1877-1889.
- 692 25. Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, et al. Donor species
- 693 richness determines faecal microbiota transplantation success in inflammatory bowel disease. J
- 694 Crohns Colitis 2016; 10: 387-394.

- 695 26. Gutin L, Piceno Y, Fadrosh D, Lynch K, Zydek M, Kassam Z, et al. Fecal microbiota transplant
- 696 for Crohn disease: a study evaluating safety, efficacy, and microbiome profile. United European

697 Gastroenterol J 2019; 7: 807-814.

- 698 27. Sokol H, Landman C, Seksik P, Berard L, Montil M, Nion-Larmurier I, et al. Fecal microbiota
- transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study.
- 700 Microbiome 2020; 8: 12.
- 28. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, et al. Precision microbiome
- reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015; 517:
- 703 205-208.
- Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt
 biotransformations by intestinal bacteria. Gut Microbes 2016; 7: 22-39.
- 30. Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, et al. Bile acid metabolites control T_H 17 and T_{reg} cell differentiation. Nature 2019; 576: 143-148.
- 31. Campbell C, McKenney PT, Konstantinovsky D, Isaeva OI, Schizas M, Verter J, et al. Bacterial
- metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 2020; 581:
- 710 475-479.
- 32. Li W, Hang S, Fang Y, Bae S, Zhang Y, Zhang M, et al. A bacterial bile acid metabolite
 modulates T_{reg} activity through the nuclear hormone receptor NR4A1. Cell Host Microbe 2021;
 29: 1366-1377.
- 33. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut
 microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol 2019;
 4: 293-305.
- 34. Paik D, Yao L, Zhang Y, Bae S, D'Agostino GD, Kim E, Franzosa EA, et al. Human gut bacteria
 produce T_H17-modulating bile acid metabolites. bioRxiv. 2021; doi: 10.1101/2021.01.08.425913.

719 35. Connors J, Dunn KA, Allott J, Bandsma R, Rashid M, Otley AR, et al. The relationship between 720 fecal bile acids and microbiome community structure in pediatric Crohn's disease. ISME J 2020; 721 14:702-713.

722 36. Mintz M, Khair S, Grewal S, LaComb JF, Park J, Channer B, et al. Longitudinal microbiome 723 analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium 724 difficile infection and/or ulcerative colitis. PLoS One 2018; doi: 10.1371/journal.pone.0190997.

- 725 37. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of 726 inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753. 727 38. Vashist NM, Samaan M, Mosli MH, Parker CE, MacDonald JK, Nelson SA, et al. Endoscopic 728 scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Db Syst Rev. 2018: 729
- doi: ARTN CD01145010.1002/14651858.CD011450.pub2.
- 730 39. Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, et al. Responsiveness of 731 endoscopic indices of disease activity for Crohn's disease. Am J Gastroenterol 2017; 112: 1584-
- 732 1592.
- 733 40. Buchfink B, Xie C, Huson DH. Fast and sensitive protein alignment using DIAMOND. Nat 734 Methods 2015; 12: 59-60.
- 735 41. Robertson CE, Harris JK, Wagner BD, Granger D, Browne K, Tatem B, et al. Explicet: 736 graphical user interface software for metadata-driven management, analysis and visualization of 737 microbiome data. Bioinformatics 2013; 29: 3100-3101.
- 738 42. DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, et al. Drug-739 resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 2019; 381: 740 2043-2050.
- 741 43. Leung V, Vincent C, Edens TJ, Miller M, Manges AR. Antimicrobial resistance gene 742 acquisition and depletion following fecal microbiota transplantation for recurrent Clostridium 743 difficile infection. Clin Infect Dis 2018; 66: 456-457.

- 44 Solbach P, Chhatwal P, Woltemate S, Tacconelli E, Buhl M, Gerhard M, et al. BaiCD gene
 cluster abundance is negatively correlated with Clostridium difficile infection. PLoS One 2018; doi:
- 746 10.1371/journal.pone.0196977.
- 45. Amrane S, Bachar D, Lagier JC, Raoult D. Clostridium scindens is present in the gut
 microbiota during Clostridium difficile infection: a metagenomic and culturomic analysis. J Clin
- 749 Microbiol 2018; doi: 10.1128/JCM.01663-17.
- 46. Song Z, Cai Y, Lao X, Wang X, Lin X, Cui Y, et al. Taxonomic profiling and populational
- 751 patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome.
- 752 Microbiome 2019; doi: 10.1186/s40168-019-0628-3.
- 47. Dong Z, Lee BH. Bile salt hydrolases: structure and function, substrate preference, and
 inhibitor development. Protein Sci 2018; 27: 1742-1754.
- 48. Foley MH, O'Flaherty S, Barrangou R, Theriot CM. Bile salt hydrolases: gatekeepers of bile
- acid metabolism and host-microbiome crosstalk in the gastrointestinal tract. PLoS Pathog 2019;
- 757 15: doi: 10.1371/journal.ppat.1007581.
- 49. Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, et al. Connecting
- dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut2013; 62: 531-539.
- 50. Das P, Marcišauskas S, Ji B, Nielsen J. Metagenomic analysis of bile salt biotransformation
 in the human gut microbiome. BMC Genomics 2019; doi: 10.1186/s12864-019-5899-3.
- 51. Sato Y, Atarashi K, Plichta DR, Arai Y, Sasajima S, Kearney SM, et al. Novel bile acid
 biosynthetic pathways are enriched in the microbiome of centenarians. Nature 2021; 599: 458464.
- 766
- 767 Supporting information

- 768 S1 text. Institutional review board approved protocol for ClinicalTrials.gov 769 ID:NCT03268213.
- S2 text. Institutional review board approved protocol for Clinical Trials.gov ID
 NCT03267238.
- 772 **S1 Table.** Transparent Reporting of Evaluations with Nonrandomized Designs (TREND)
- 773 checklist.
- 774 S2 Table. Chromatographic and quantitation strategy for the BA and internal standards
- 775 **(ISTD) measured.**
- 776 **S3 Table. Bile acid metabolizing enzyme genes used in DIAMOND custom search.**
- 777 S4 Table. Individual characteristics of the rCDI IBD recipients.
- 778 **S5** Table. Individual characteristics of the rCDI + IBD recipients.
- 779 **S6** Table. Individual characteristics of the UC rCDI recipients.
- 780 S7 Table. Individual characteristics of the CD rCDI recipients.
- 781 S8 Table. Significant (FDR < 0.05) estimated pre-FMT recipient/donor ratios (95% Cl) of the
- relative abundances of Actinobacteria genus level OTUs for each of the four recipientgroups.
- 784 S9 Table. Significant (FDR < 0.05) estimated pre-FMT recipient/donor ratios (95% CI) of the
- relative abundances of Bacteroidetes genus level OTUs for each of the four recipientgroups.
- 787 S10 Table. Significant (FDR < 0.05) estimated pre-FMT recipient/donor ratios (95% CI) of
- the relative abundances of Ruminococcaceae (Clostridium Group IV) genus level OTUs for
- 789 each of the four recipient groups.
- 790 S11 Table. Significant (FDR < 0.05) estimated pre-FMT recipient/donor ratios (95% CI) of
- the relative abundances of Lachnospiraceae (Clostridium Group XIVa) genus level OTUs
- 792 for each of the four recipient groups.

793	S12 Table. Significant (FDR < 0.05) estimated pre-FMT recipient/donor ratios (95% CI) of
794	the relative abundances of Bacilli genus level OTUs for each of the four recipient groups.
795	S13 Table. Significant (FDR < 0.05) estimated pre-FMT recipient/donor ratios (95% CI) of
796	the relative abundances of Proteobacteria genus level OTUs for each of the four recipient
797	groups.
798	S14 Table. Significant (FDR < 0.05) estimated pre-FMT recipient/donor ratios (95% CI) of
799	the relative abundances of genus level OTUs in "Other Taxa" for each of the four recipient
800	groups.
801	S15 Table. Median Pre-FMT BA levels (pmol/g wet weight of stool or μ M) ± IQR in donor
802	and four recipient groups.
803	S16 Table. Post-hoc Dunns test P-values with Benjamini–Hochberg adjustments, for 19
804	pre-FMT median BA metabolite levels in the four recipient groups (see S15 Table).
805	S17 Table. Estimated coefficient (95% CI) with baiE cpm as covariate and baiCD cpm as
806	outcome in linear mixed model treating FMT group as clustering effect.
807	S18 Table. Estimated coefficient (95% CI) with R. gnavus 3 α -HSDH/E. lenta 3 α -HSDH/E.
808	lenta 3 β -HSDH cpm as covariate and R. gnavus 3 β -HSDH/E. lenta 3 α -HSDH cpm at 80%
809	identity as outcome in linear mixed model treating FMT group as clustering effect
810	S19 Table. Correlation between <i>B. dorei</i> 3 β -reductase, 5 β -reductase and 3 β -HSDH.
811	

















